At a conference in New Orleans last month, I stood up and told a room full of investors to sell small modular reactor companies. I specifically called out OKLO – a company with no sales, no approvals, and a market cap in the billions. It’s down $30 since that conference. In the War Room, I … Continued
What Bryan’s worst trade revealed about our next play
One of the biggest indicators of a winning insider buy is when insiders buy while the stock is getting hammered. Take Exact Sciences (EXAS), for example. Back in November 2024, the stock was nosediving. Normally, this wouldn’t be anything to write home about. Stocks go up and down for a variety of reasons. But as … Continued
Dow +700. Perfect hedge timing.
I hate losing money. But sometimes the trades that hurt the most end up teaching you everything about how markets really work. Bryan called it my “biggest fly in the ointment trade of the entire year.” He wasn’t wrong. The Trade Everyone Thought Was Stupid While everyone was paying $100 for every $1 in sales … Continued
Once you know this strategy, you can find buy opportunities on big swings.
I’ve Been Tracking CEO Million-Dollar Buys to Pick Bottoms for Years – But My Partner Bryan’s New “Cash Code X” System Is Making Me Question Everything About Bottom-Picking
Why I’m Betting Big on Pfizer While Everyone Ignores 10x PE Healthcare Stocks
How We Made $98 Per Share Trading Hurricane Season (And Why We Exited at the Perfect Time)
Most acquirers are idiots who pay massive premiums for earnings. Kimberly-Clark just proved they’re not most acquirers. KMB is buying Kenvue (the J&J spinoff with Tylenol, Listerine, all that stuff) at 16 times earnings. That’s the exact same multiple KMB trades at. When’s the last time you saw an acquirer get a company at their … Continued